Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Rebates: Defeat In Finance Committee May Set Key Precedent

This article was originally published in RPM Report

Executive Summary

Democratic Sen. Bill Nelson of Florida may have made a tactical error in bringing up an amendment to mandate drug rebates under Medicare Part D during the Senate Finance Committee’s markup of health reform legislation.

You may also be interested in...



Medicare Part D "Downpayment": Coverage Gap Relief Added To Senate Health Reform Bill

Senate compromise attempts to meet in the middle by offering additional donut hole relief without using Part D dual-eligible rebates to pay for closing the coverage gap altogether.

Counting the Votes: Democrats Consider Their Public Options On Health Reform and Reconciliation

Democrats always feared having the health care reform debate carrying over past August. Now it’s October. Media coverage of chaotic town hall meetings, intra-party disputes, and a united Republican opposition show how prescient the Democrats were to worry about debate after the summer holidays. Democrats are now starting to consider how they’ll vote on a fi nal bill. Here’s what it could look like if the legislation goes through the Congressional shortcut of budget reconciliation and includes a public plan.

Obamacare: The Politics of Health Care Reform Entering the Endgame

There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel